Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Human NK cells confer protection against HIV-1 infection in humanized mice
Can M. Sungur, Qiankun Wang, Ayşe N. Ozantürk, Hongbo Gao, Aaron J. Schmitz, Marina Cella, Wayne M. Yokoyama, Liang Shan
Can M. Sungur, Qiankun Wang, Ayşe N. Ozantürk, Hongbo Gao, Aaron J. Schmitz, Marina Cella, Wayne M. Yokoyama, Liang Shan
View: Text | PDF
Research Article Immunology

Human NK cells confer protection against HIV-1 infection in humanized mice

  • Text
  • PDF
Abstract

The role of NK cells against HIV-1 infections remains to be elucidated in vivo. While humanized mouse models potentially could be used to directly evaluate human NK cell responses during HIV-1 infection, improved functional development of human NK cells in these hosts is needed. Here, we report the humanized MISTRG-6-15 mouse model, in which NK cells were quick to expand and exhibit degranulation, cytotoxicity, and proinflammatory cytokine production in nonlymphoid organs upon HIV-1 infection but had reduced functionality in lymphoid organs. Although HIV-1 infection induced functional impairment of NK cells, antiretroviral therapy reinvigorated NK cells in response to HIV-1 rebound after analytic treatment interruption. Moreover, a broadly neutralizing antibody, PGT121, enhanced NK cell function in vivo, consistent with antibody-dependent cellular cytotoxicity. Monoclonal antibody depletion of NK cells resulted in higher viral loads in multiple nonlymphoid organs. Overall, our results in humanized MISTRG-6-15 mice demonstrated that NK cells provided direct anti–HIV-1 responses in vivo but were limited in their responses in lymphoid organs.

Authors

Can M. Sungur, Qiankun Wang, Ayşe N. Ozantürk, Hongbo Gao, Aaron J. Schmitz, Marina Cella, Wayne M. Yokoyama, Liang Shan

×

Figure 7

PGT121 antibody-mediated viral suppression enhances NK cell functionality.

Options: View larger image (or click on image) Download as PowerPoint
PGT121 antibody-mediated viral suppression enhances NK cell functionalit...
MISTRG-6-15 mice were infected with HIV-1BAL. 2 doses (20 mg/kg) of PGT121 (n = 9), PGT121GRLR (n = 5), or PBS (n = 10) were administered on days 14 and 17 after infection. Blood samples were collected on days 14 and 20. Tissues were collected on day 20. (A) Plasma viral load before and after antibody treatment. Lines connect individual mice. P values were calculated using 2-way ANOVA with Šidák’s multiple comparison test. (B) Plasma viral load fold change from day 14 to day 20. P values were calculated using 1-way ANOVA with Tukey’s multiple comparison post test. (C) Copies of cavRNA in spleen, lung, and LN. (D) Percentage p24+ of CD3+CD8– cells in spleen, lung, and LN. (E) Expression of CD107a or GZMB in NK cells in the spleen, lung, and LN. NK cells purified from tissues were stimulated with PMA/ionomycin ex vivo for 4 hours before flow cytometry analysis. PGT121 (n = 3), PGT121GRLR (n = 4), and PBS (n = 3). Data displayed as mean ± SEM. In (C–E) P values for each tissue were calculated using 2-way ANOVA with Tukey’s multiple comparison post test. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts